Search





Search





Sitryx Regains Rights To SYX-1042 For Chronic Autoimmune And Inflammatory Diseases

ReutersAug 8, 2025 4:02 PM

Aug 8 (Reuters) - SITRYX:

SITRYX REGAINS RIGHTS TO SYX-1042 ITACONATE MIMETIC FOR CHRONIC AUTOIMMUNE AND INFLAMMATORY DISEASES FROM LILLY FOLLOWING PORTFOLIO REPRIORITIZATION

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

What company Is ASML? Between ASML and AMD, Which Is a Better Investment?

TradingKey - ASML Holding N.V. (NASDAQ: ASML) is not a chip designer; instead, it's best understood as a supplier of equipment for producing semiconductors (sometimes referred to as chips).

Amazon Stock: 4 Pillars Supporting a Buy Thesis in a Cautious Market

TradingKey - In 2025, AMZN has underperformed vs. the rest of the S&P 500 due to concerns about high infrastructure spending and uncertainty around the timing of cash flow from AI investments.

SpaceX IPO Guide: Can You Buy SpaceX IPO Shares on Robinhood? How Can Investors in Asia and Europe Buy SpaceX IPO Shares?

Looking to invest in the $1.75T SpaceX IPO? Discover if Robinhood and E*Trade offer access, and explore step-by-step guides for retail investors in Singapore, Hong Kong, the UK, and the EU to secure their shares.

The Great Bitcoin Treasury Shakeout: From "Infinite Money Glitch" to Survival of the Fittest

Analyze the 2026 Bitcoin treasury shakeout as the "infinite money glitch" fractures. Learn why 40% of firms trade below NAV, how miners are pivoting to AI, and why institutional "HODLing" is evolving into active asset management amid a volatile Q1 market correction.

What Needs to Happen for Tesla to Succeed in the Next Few Years?

TradingKey - The stock of Tesla (TSLA) is currently in contention as the bearish side has the advantage.

Tradingkey

KeyAI

